Emergence of a HER2-amplified clone during disease progression in an ALK-rearranged NSCLC patient treated with ALK-inhibitors: a case report

Anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) are the standard treatment for advanced ALK-positive non-small cell lung cancer (NSCLC) allowing survivals up to 5 years. However, duration of responses is limited by the almost certain occurrence of drug resistance. Here, we report a...

Descripción completa

Detalles Bibliográficos
Autores principales: Minari, Roberta, Gnetti, Letizia, Lagrasta, Costanza Annamaria, Squadrilli, Anna, Bordi, Paola, Azzoni, Cinzia, Bottarelli, Lorena, Cosenza, Agnese, Ferri, Leonarda, Caruso, Giuseppe, Silini, Enrico Maria, Tiseo, Marcello
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354139/
https://www.ncbi.nlm.nih.gov/pubmed/32676339
http://dx.doi.org/10.21037/tlcr.2020.04.03

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354139/
https://www.ncbi.nlm.nih.gov/pubmed/32676339
http://dx.doi.org/10.21037/tlcr.2020.04.03

Ejemplares similares